Published in Neth Heart J on September 01, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J (2015) 2.25
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol (2014) 1.71
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J (2014) 1.45
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol (2014) 1.45
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J (2015) 1.28
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J (2014) 1.26
Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J (2013) 1.13
Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. Neth Heart J (2012) 1.13
Potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands. Neth Heart J (2012) 1.04
Current discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) study. Neth Heart J (2014) 0.96
Stabilization of atherosclerotic plaques: an update. Eur Heart J (2013) 0.96
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J (2015) 0.94
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res (2014) 0.94
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Neth Heart J (2013) 0.84
Beyond lipid lowering: pleiotropic effects of statins in heart failure. Neth Heart J (2013) 0.82
Are statins more effective in male patients? Neth Heart J (2012) 0.81
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol (2015) 0.78
Lifestyle for a lifetime. Neth Heart J (2015) 0.85
Tooth brushing for a longer and healthier life. Neth Heart J (2016) 0.78
New guidelines on primary PCI for patients with STEMI: changing insights. Neth Heart J (2016) 0.75
Air pollution: 6.6 million premature deaths in 2050! Neth Heart J (2015) 0.75